Enzymaster, a German enzyme catalysts maker, has acquired China-based Sanming Minhe, in order to meet growing global demands.
Across a range of industries, including pharmaceutical, food and beverage, agriculture, consumer goods, and many other markets, manufacturers are increasingly turning to enzyme catalysts for cleaner, more efficient process technology solutions. To meet these demands, Enzymaster required additional production capacity and sought to acquire a strategically located facility utilizing equipment compatible with their Ningbo, China plant.
Enzymaster chose Fujian Sanming Minhe Pharmaceutical Technology (Sanming Minhe) because of its location in an approved industrial park, proximity to the coast offering ready access to shipping ports, and its new construction.
Located in the western Fujian province, 40% of Sanming Minhe’s capacity will be dedicated to manufacturing products using Enzymaster’s processing technology. This capacity allocation will increase Enzymaster’s overall production capacity by 50%.
The acquisition will enable Enzymaster to produce 600 metric tons annually of enzymes and compounds utilizing cleaner, greener biomanufacturing processes.
“The facility has been in operation for less than a year, so the building's design and construction are state-of-the-art,” said Mr. Michael Lv, President of Enzymaster. "The added capacity expands our ability to serve our clients worldwide. However, the extremely experienced management team with high levels of expertise was the most attractive to us.”
Dr. Daofei Huang was appointed Senior Vice President of Enzymaster and will serve as the Managing Director of Sanming Minhe. Additionally, Mr. Zongli Wang, Mr. Chufeng Liang, and Dr. Xingtao Guo will lead manufacturing, quality assurance and quality control, and pilot scaling and technical transfer, respectively. Each leader has extensive experience working on both the development and manufacturing sides of the pharmaceuticals and specialty chemicals markets. They are also each extremely familiar with the demands of serving a diverse and global customer base.
“Sanming Minhe will become the primary manufacturing facility for pharmaceutical intermediates and additional compounds in Enzymaster’s current and future pipeline,” shared Dr. Huang. “The facility includes a kilogram-level technology development center and pilot-scale production as well as robust commercial-scale production capacity. These resources will further improve our ability to serve as a collaborative R&D and commercial manufacturing partner to our growing customer base while maintaining our record of quality, confidentiality, and on-time delivery.”
